HRTX · Heron Therapeutics, Inc. /De/

Each restricted stock unit represents a contingent right to receive one share of common stock.

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

The restricted stock units vest with 25% upon the first anniversary of date of grant (May 6, 2025) and then in twelve (12) equal quarterly installments thereafter.

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Includes 11,023 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026.

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Each restricted stock unit represents a contingent right to receive one share of common stock.

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Includes 11,023 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026.

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Includes 16,646 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025.

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Each restricted stock unit represents a contingent right to receive one share of common stock.

Includes 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025.

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Each restricted stock unit represents a contingent right to receive one share of common stock.

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Each restricted stock unit represents a contingent right to receive one share of common stock.

Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

On January 30, 2026, the Reporting Person was granted 800,336 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.

Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

On January 30, 2026, the Reporting Person was granted 188,314 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.

Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

On January 30, 2026, the Reporting Person was granted 216,561 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.

The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

On January 30, 2026, the Reporting Person was granted 188,314 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.